A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Phase 2 Terminated
50 enrolled 18 charts
AcceleRET-Lung
Phase 3 Terminated
223 enrolled 18 charts
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Phase 2 Terminated
14 enrolled 16 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
VIGOR
Phase 4 Terminated
5 enrolled
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Phase 3 Terminated
8 enrolled 7 charts
BREC
Phase 3 Terminated
382 enrolled 15 charts
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Phase 1/2 Terminated
67 enrolled 24 charts
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
Phase 2 Terminated
14 enrolled 14 charts
Safety Study of SEA-CD40 in Cancer Patients
Phase 1 Terminated
159 enrolled
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Phase 1/2 Terminated
201 enrolled 71 charts
Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients
Phase 2 Terminated
108 enrolled
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 1 Terminated
61 enrolled
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Phase 1 Terminated
111 enrolled
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Phase 2 Terminated
3 enrolled 11 charts
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Terminated
39 enrolled 9 charts
STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
Phase 2 Terminated
72 enrolled
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Phase 3 Terminated
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
Phase NA Terminated
4 enrolled 7 charts
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase 2/3 Terminated
135 enrolled
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Phase 2 Terminated
66 enrolled 17 charts
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Phase 3 Terminated
149 enrolled 17 charts
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Phase 3 Terminated
2 enrolled 6 charts
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
Phase 3 Terminated
8 enrolled 9 charts
A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
Phase 2 Terminated
7 enrolled 9 charts
NA_00067809
Phase 2 Terminated
3 enrolled 5 charts
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase 2 Terminated
17 enrolled 10 charts
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase 3 Terminated
313 enrolled 14 charts
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Phase 1/2 Terminated
81 enrolled
Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC
Phase 2 Terminated
24 enrolled
Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer
Phase 2 Terminated
1 enrolled 5 charts
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase 2 Terminated
22 enrolled 11 charts
Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Phase 1 Terminated
4 enrolled
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Phase 4 Terminated
61 enrolled
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
Phase 2 Terminated
1 enrolled 3 charts
LCCC1407
Phase 2 Terminated
1 enrolled 5 charts
CAPPA-2
Phase 3 Terminated
57 enrolled
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Phase 3 Terminated
34 enrolled 6 charts
TIME
Phase 2/3 Terminated
222 enrolled
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
Phase 1 Terminated
15 enrolled 10 charts
DISTAL-2
Phase 3 Terminated
84 enrolled
Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
Phase 2 Terminated
3 enrolled 3 charts
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Phase 2 Terminated
45 enrolled 4 charts
Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
Phase 2 Terminated
38 enrolled
HALO
Phase 1 Terminated
82 enrolled
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Terminated
54 enrolled 13 charts
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
Phase 3 Terminated
839 enrolled
TOP0602
Phase 2 Terminated
101 enrolled 12 charts
Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 2 Terminated
17 enrolled 8 charts
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
Phase 1 Terminated
41 enrolled 17 charts